NCT01147341View on ClinicalTrials.gov

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Cimzia

prefilled 200mg Cimzia syringe SC q 2 weeks

DRUG

Placebo

prefilled saline syringe

Trial Locations (12)

11787

Rheumatology Associates of Long Island, Smithtown

14127

Buffalo Rheumatology, Orchard Park

16635

Altoona Center for Clinical Research, Duncansville

26301

Mountain State Clinical Research, Clarksburg

34239

Sarasota Arthritis Research Center, Sarasota

35801

Rheumatology Associates of N. Alabama, Huntsville

53154

Rheumatology and Immunotherapy Center, Oak Creek

68114

Westroads Medical Group, Omaha

68516

Physician Research Collaboration, LLC, Lincoln

85037

Arizona Arthritis and Rhematolgy Research, Phoenix

85381

Sun Valley Arthritis Center, Ltd., Peoria

07960

Morristown Memorial Hospital, Morristown

Sponsors

Collaborators (1)

UCB Pharma
All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Michael Schiff, MD

INDIV